Bokf Na Reduces Holdings in Intuitive Surgical, Inc. $ISRG

Key Points

• Bokf Na cut its stake in Intuitive Surgical (NASDAQ:ISRG) by 17.9% in Q4, selling 3,239 shares and leaving it with 14,810 shares valued at $8.388 million.
• Company insiders sold a total of 5,906 shares in the last quarter worth about $2.91 million (notable sales by SVPs Patricia Wadors and Mark Brosius), with insiders now owning 0.60% of the company.
• Analysts hold a consensus "Moderate Buy" on ISRG with an average price target of $581.91 (18 Buys, 7 Holds, 1 Sell), and Intuitive recently beat the quarter with $2.50 EPS and $2.77 billion in revenue, up 23% year-over-year.

Bokf Na lowered its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 17.9% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 14,810 shares of the medical equipment provider's stock after selling 3,239 shares during the period. Bokf Na's holdings in Intuitive Surgical were worth $8,388,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the company. Holos Integrated Wealth LLC bought a new stake in shares of Intuitive Surgical in the fourth quarter worth $25,000. Newbridge Financial Services Group Inc. increased its stake in shares of Intuitive Surgical by 300.0% in the fourth quarter. Newbridge Financial Services Group Inc. now owns 44 shares of the medical equipment provider's stock worth $25,000 after buying an additional 33 shares during the last quarter. Greykasell Wealth Strategies Inc. bought a new stake in shares of Intuitive Surgical in the third quarter worth $27,000. Olistico Wealth LLC bought a new stake in shares of Intuitive Surgical in the fourth quarter worth $28,000. Finally, Caitlin John LLC bought a new stake in shares of Intuitive Surgical in the third quarter worth $30,000. Hedge funds and other institutional investors own 83.64% of the company's stock.

Insider Activity at Intuitive Surgical

In other news, SVP Patricia L. Wadors sold 220 shares of the business's stock in a transaction on Friday, February 27th. The shares were sold at an average price of $499.71, for a total transaction of $109,936.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Mark Brosius sold 2,362 shares of the business's stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $498.68, for a total transaction of $1,177,882.16. Following the transaction, the senior vice president directly owned 3,554 shares of the company's stock, valued at approximately $1,772,308.72. This trade represents a 39.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 5,906 shares of company stock valued at $2,907,726. Company insiders own 0.60% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Mizuho set a $525.00 price target on shares of Intuitive Surgical and gave the stock a "neutral" rating in a research note on Monday, April 13th. HSBC dropped their price target on shares of Intuitive Surgical from $653.00 to $604.00 and set a "buy" rating for the company in a research note on Wednesday, April 22nd. Argus dropped their price target on shares of Intuitive Surgical from $630.00 to $560.00 and set a "buy" rating for the company in a research note on Wednesday, February 4th. The Goldman Sachs Group lifted their price target on shares of Intuitive Surgical from $609.00 to $621.00 and gave the stock a "buy" rating in a research note on Wednesday, April 22nd. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Intuitive Surgical from $625.00 to $550.00 and set an "overweight" rating for the company in a report on Wednesday, April 22nd. Eighteen analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Intuitive Surgical currently has a consensus rating of "Moderate Buy" and an average target price of $581.91.

Intuitive Surgical Price Performance

Intuitive Surgical stock opened at $451.73 on Thursday. The company has a market cap of $159.98 billion, a PE ratio of 54.76, a P/E/G ratio of 3.61 and a beta of 1.51. The company has a fifty day moving average price of $473.00 and a two-hundred day moving average price of $517.34. Intuitive Surgical, Inc. has a 12 month low of $427.84 and a 12 month high of $603.88.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last released its quarterly earnings data on Tuesday, April 21st. The medical equipment provider reported $2.50 EPS for the quarter, topping analysts' consensus estimates of $2.08 by $0.42. The firm had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.62 billion. Intuitive Surgical had a net margin of 28.15% and a return on equity of 15.98%. The firm's revenue was up 23.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.81 earnings per share. Equities research analysts anticipate that Intuitive Surgical, Inc. will post 8.57 earnings per share for the current year.

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon's hand movements into finer, scaled motions of small instruments inside the patient. Intuitive's business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.